Biotest AG is a Germany‑based developer, manufacturer and marketer of plasma‑derived biologic therapeutics used mainly in clinical immunology, haematology and intensive care medicine; it operates fractionation and manufacturing facilities in Dreieich, runs plasma collection centres in Europe, and reported revenue of €726.3m in 2024 while employing ~2,300–2,500 people worldwide[1][3].[1]
High‑Level Overview
- Concise summary: Biotest AG produces plasma‑protein and biotherapeutic drugs (immunoglobulins, clotting factors, albumin and specialty hyperimmune preparations) for severe and often chronic conditions, marketing globally through its subsidiaries and partners while owning upstream plasma collection and fractionation capacity in Germany and other European countries[1][3].[1][3]
- What product it builds (portfolio company framing): Biotest’s core products are plasma‑derived therapeutics such as immunoglobulins (e.g., Intratect, Yimmugo), clotting factor concentrates (e.g., Haemoctin, Haemonine), albumin (Albiomin), hyperimmune globulins (Hepatect, Cytotect, Varitect) and adjunct products like Pentaglobin and Trimodulin for infections and inflammatory conditions[2].[2]
- Who it serves: Hospitals, hematologists, immunologists, intensive care units and specialist clinics treating immune deficiencies, haemophilia, viral exposures and critically ill patients in Europe and selected global markets[1][2].[1][2]
- What problem it solves: Provides life‑saving and life‑improving therapies where recombinant or small‑molecule alternatives are limited — replacing deficient plasma proteins, preventing/treating infections via pooled or hyperimmune immunoglobulins, and supporting haemostatic function in bleeding disorders[1][2].[1][2]
- Growth momentum: Biotest has been expanding manufacturing capacity under its “Biotest Next Level” program (doubling Dreieich capacity toward ~3 million litres plasma processing by 2026) and reported €726.3m revenue for 2024; the company was delisted from the Frankfurt exchange in June 2025 after private restructuring of ownership[1][6].[1][6]
Origin Story
- Founding and early history: Biotest was founded in 1946 in Frankfurt as Biotest Serum‑Institut GmbH by Carl Adolf Schleussner and Dr. Hans Schleussner and initially focused on serology and blood‑typing research; the company produced its first plasma product (Biseko) in 1949 and moved operations to Dreieich in the 1960s as it scaled fractionation and manufacturing[4].[4]
- Evolution: The firm reorganized as Biotest AG in 1986 and went public in 1987 to support international expansion; over subsequent decades it launched a range of polyspecific and hyperimmune immunoglobulins, automated diagnostic systems, and plasma collection capabilities, building an integrated value chain from plasma collection through manufacturing to global marketing[4][3].[4][3]
- Recent corporate change: In 2025 Biotest was delisted from the Frankfurt stock exchange as part of ownership changes, while continuing to scale production capacity at Dreieich under the Next Level project[6][1].[6][1]
Core Differentiators
- Integrated plasma value chain: Owns/plans proprietary plasma collection centres and large‑scale fractionation/manufacturing at Dreieich, enabling control over a critical raw material and supply resilience uncommon among smaller biologics firms[1][3].[1][3]
- Broad plasma‑derived portfolio: A wide range of standard immunoglobulins, clotting factors and specialised hyperimmune products across clinical immunology, haematology and intensive care gives diversified revenue streams and clinical utility[2][1].[2][1]
- Manufacturing scale‑up program: “Biotest Next Level” investment that doubles processing capacity (target ~3 million litres) through 2026 positions the company to meet growing global demand for plasma‑derived medicines[1].[1]
- Regulatory and clinical track record: Long history of product approvals and iterative product improvements (e.g., virus‑inactivated factor VIII) since the 1970s–1990s, reflecting regulatory experience in plasma product safety and quality[4][2].[4][2]
- European specialist positioning: Strong regional presence with subsidiaries and production in central Europe, enabling rapid supply to European markets and partnerships elsewhere[1][3].[1][3]
Role in the Broader Tech / Biopharma Landscape
- Trend alignment: Biotest sits at the intersection of rising global demand for plasma‑derived therapies (aging populations, wider diagnostic identification of immune deficiencies) and renewed focus on biologic and blood‑product supply chain security[1][3].[1][3]
- Timing and market forces: Recent supply shortages and heightened regulatory scrutiny on plasma sourcing have increased the strategic value of vertically integrated fractionators with dedicated plasma collection; Biotest’s capacity expansion addresses those supply pressures[1][6].[1][6]
- Influence on ecosystem: As a midsize specialist with production capabilities, Biotest serves as a supplier and partner to hospitals and smaller biotech firms needing clinical‑grade plasma products, and contributes expertise in plasma fractionation and immunoglobulin development to the broader field[3][2].[3][2]
Quick Take & Future Outlook
- What’s next: Execution of the Biotest Next Level capacity ramp to reach ~3 million litres processing by 2026 will be the near‑term value driver, alongside commercial uptake of specialty products such as Trimodulin and continued geographic expansion via subsidiaries and partners[1][2].[1][2]
- Risks and shaping trends: Key risks include plasma supply constraints, pricing and reimbursement pressures in major markets, and competition from other plasma fractionators and recombinant alternatives; favorable trends include growing demand for immunoglobulins and health systems’ interest in securing plasma supply chains[1][6].[1][6]
- How influence may evolve: If Biotest successfully completes its capacity expansion and sustains product quality, it can strengthen its role as a European supply hub for plasma‑derived therapeutics and increase bargaining power with payers and distributors; conversely, ownership or strategy shifts after delisting could redirect priorities toward private strategic goals[1][6].[1][6]
Quick reiteration: Biotest is a long‑established, Europe‑focused plasma‑fractionation specialist that combines product breadth with upstream plasma sourcing and a current capacity expansion program — its near‑term trajectory will hinge on completing manufacturing scale‑up and managing plasma supply and market access dynamics[1][3][6].[1][3][6]
